Venture Global Announces Closing of $2,500,000,000 Senior Secured Notes by Venture Global Plaquemines LNG, LLC
Venture Global Inc. (“Venture Global”) announced today that its subsidiary, Venture Global Plaquemines LNG, LLC (“VGPL”) has closed an offering of $2,500,000,000 aggregate principal amount of senior secured notes, which has been issued in two series: (i) a series of 7.50% senior secured notes due 2033 in an aggregate principal amount of $1,250,000,000 (the “2033 Notes”) and (ii) a series of 7.75% senior secured notes due 2035 in an aggregate principal amount of $1,250,000,000 (the “2035 Notes” and, together with the 2033 Notes, the “Notes”). The 2033 Notes will mature on May 1, 2033 and the 2035 Notes will mature on May 1, 2035.
VGPL intends to use the net proceeds from the offering to (i) prepay certain amounts outstanding under VGPL’s existing senior secured first lien credit facilities (the “Existing Credit Facilities”) and (ii) pay fees and expenses in connection with the offering. The notes are guaranteed by Venture Global Gator Express, LLC (VGPL’s affiliate). The Notes are secured on a pari passu basis by a first-priority security interest in the assets that secure the Existing Credit Facilities.
The Notes were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdictions, and the Notes may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Notes, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About Venture Global
Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s first facility, Calcasieu Pass, commenced producing LNG in January 2022. The company’s second facility, Plaquemines LNG, achieved first production of LNG in December 2024. The company is currently constructing and developing over 100 MTPA of nameplate production capacity to provide clean, affordable energy to the world. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.
Forward-Looking Statements
This press release contains certain statements that may include “forward-looking statements.” All statements, other than statements of historical or present facts or conditions, included herein are “forward-looking statements.” Included among “forward-looking statements” are, among other things, statements regarding Venture Global’s business strategy, plans and objectives, including the use of proceeds from the offering. Venture Global believes that the expectations reflected in these “forward-looking statements” are reasonable, they are inherently uncertain and involve a number of risks and uncertainties beyond Venture Global’s control. In addition, assumptions may prove to be inaccurate. Actual results may differ materially from those anticipated or implied in “forward-looking statements” as a result of a variety of factors. These “forward-looking statements” speak only as of the date made, and other than as required by law, Venture Global undertakes no obligation to update or revise any “forward-looking statement” or provide reasons why actual results may differ, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421263375/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Antibody Solutions Launches Single Plasma B-Cell Services through Cellestive Discovery Platform22.4.2025 13:00:00 CEST | Press release
New, exclusive capability will allow antibody discovery clients to access more hits and more screening data than competing technologies Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first time, single plasma B-cell discovery services will be part of the company’s exclusive Cellestive antibody discovery platform. The new capability completes a trifecta of B-cell services offered through Cellestive, which already includes discovery pathways for both activated and memory B-cells. The new plasma B-cell service is projected to be of particular value to clients pursuing difficult targets in antibody discovery, enabling them to leverage new processes and technologies while accessing broader, deeper data to inform their decision-making. “This really rounds out our Cellestive platform and allows us to robustly and efficiently interrogate single plasma B-cells for our clients,” said John Kenney, Phd, co-founder and president o
Sun Nuclear Announces Completion of Transition to CE Class IIb EU MDR Certification for Key Quality Management Solutions22.4.2025 12:04:00 CEST | Press release
SunCHECK® Software, SRS MapCHECK® and SunSCAN™ 3D DevicesAmong 15+ Solutions Awarded New Certification Sun Nuclear, a Mirion Medical company, announced today that its SunCHECK® Quality Management software and key radiation therapy Quality Assurance (QA) devices have been awarded CE Class IIb certification under the European Medical Devices Regulation 2017/745 (EU MDR). The transition to EU MDR Class IIb recognizes the safety and performance of Sun Nuclear solutions and confirms compliance with stringent safety requirements. Sun Nuclear solutions awarded Class IIb certification include: The SunCHECK® Platform, a comprehensive software application facilitating essential Patient and Machine QA workflows and centralized data management; Patient-specific QA solutions, including the ArcCHECK®, ArcCHECK®-MR, MapCHECK® 3 and SRS MapCHECK® devices, for measurement of radiation dose distributions against planned doses; Machine QA solutions, including the Daily QA™ 3, Daily QA™ 3-MR, IC PROFILER™
Regula Becomes the First to Verify All Dynamic Security Features in Remote Document Checks22.4.2025 12:00:00 CEST | Press release
With the recent update of its Document Reader SDK, Regula became the first identity verification (IDV) vendor to make it possible to verify all the dynamic security features of documents in real time. With the latest addition of Dynaprint® checks, the solution ensures more robust physical document authentication during remote onboarding. The innovation has arrived at a time when 58% of businesses globally face fake or modified IDs during digital onboarding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422724077/en/ Dynaprint in the Arizona’s driver’s license (Photo: Regula) Dynaprint® is a dynamic security feature consisting of two different images printed with lenticular technology. Depending on the angle of observation, only one image is visible at a time. Like all other dynamic security features, Dynaprint is crucial for securing identity documents from tampering, since it’s a tricky task to fake it without special e
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression22.4.2025 12:00:00 CEST | Press release
Highlights: Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on track to disclose top-line 6-week primary endpoint results in late June. “Completing dosing of all participants in Part A of our 005 trial marks a critical milestone in our mission to address the pressing unmet need in treatment resistant depression,” said Kabir Nath, CEO Compass Pathways. “We are proud of this achievement which reflects our team’s commitment to scient
Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting22.4.2025 10:37:00 CEST | Press release
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for Cancer Research Annual Meeting (AACR) 2025 being held in Chicago April 25-30, 2025. In the poster, entitled “Preferential tumor uptake and retention of EGL-001, an anti-CTLA4-IL2 mutein fusion antibody achieving selective tumor Treg depletion”. Egle Therapeutics unveils preclinical biodistribution data on EGL-001, a novel anti-CTLA4-IL2 mutein fusion antibody designed to selectively deplete tumor-infiltrating regulatory T cells (Tregs). EGL-001 mode of action combines competitive inhibition of IL-2 signaling and potent downregulation of surface CD25, leading to induction of Treg apoptosis. In vivo EGL-001 preferentially bound to the surface of Tregs due to their high CTLA-4 and CD25 expression and depleted them from the tumor microenvironment without affecting other immun
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom